Education Blog for Healthcare Professionals

Apixaban (Eliquis®) – Another New Oral Anticoagulant

Good news.  Another one of the new oral anticoagulants in development,  Apixaban (Eliquis®), has moved forward.  On May 20th, 2011, the European Medicines Agency (EMA) approved Eliquis® for DVT prevention after orthopedic surgery (hip and knee replacement) in the 27 countries of the European Community. In the U.S., however, Eliquis® is still some way away from getting FDA approval and coming onto the market.

Eliquis® is an anticoagulant, a factor Xa inhibitor, that has the same advantages as the other new oral anticoagulants, such as Pradaxa® (Dabigatran) and Xarelto® (Rivaroxaban): (a) no need for monitoring of its anticoagulant effect (i.e. no need to determine INRs), (b) no influence of vitamin K in the diet on anticoagulant effect, (c) active within a few hours of being taken as a tablet, and (c) out of the system within approximately 1 1/2 days after stopping it, so easier to manage at time of surgeries and procedures, such as colonoscopies.

As for DVT and PE treatment: two large phase 3 clinical studies with Apixaban are still ongoing : (a) a treatment trial of Apixaban versus Warfarin for 6 months in symptomatic DVT and PE, and (b) an extended VTE treatment trial comparing Apixaban to placebo [www.clinicaltrials.gov].

Addendum:  On Aug 28th, 2011, the large atrial fibrillation trial comparing Apixaban with warfarin was published in the NEJM.  A new blog entry discussing this trial can be found here.

Disclosure: I have no financial disclosures relevant to the content of this blog post.

Last updated: Aug 28th, 2011

Tags: , , , ,

This entry was posted by Clot Connect on at and is filed under Anticoagulants, Therapy, Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.